Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
BOSTON and HEIDELBERG, Germany, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Molecular Health today announced an expanded strategy for its novel Engineus™ technology platform to include a wide range of healthcare decision support products. Based on the most comprehensive biomedical data warehouse in the world, Engineus™ now offers highly-scalable precision medicine applications across the major healthcare categories: diagnostics, clinical decision support, therapeutics discovery and development.
Engineus™ is a global, unique, and integrated biomedical reference knowledge system that provides healthcare professionals the decision support capabilities they need to optimally leverage the opportunities of big data in healthcare. Engineus™ is expert-curated, quality-controlled, and constantly growing and being refined to make it optimally positioned to improve the efficiency of global healthcare, as the broadest of any data-driven platforms available today.
Engineus™ provides clinicians, lab partners and pharmaceutical companies the ability to make precise and individualized evidence-based diagnostic, clinical and therapeutic decisions by combining biomedical reference knowledge with best-in-breed analytics, data display and reporting.
Engineus™ is powered by data from 24 million scientific and medical publications, 76,000 drug-to-drug interactions, 6,000 biomarker facts for drug efficacy and safety, 85,000 gene variants, 40,000 drugs, 109,000 clinical trials, 270,000 protein interactions and 7 million patient medical records for drug safety among other data.
“Big data is changing the way healthcare is practiced today and further evolving the adoption of precision medicine,” said Lutz Voelker, CEO of Molecular Health. “The market need to improve healthcare efficiency grows exponentially every day. With our Engineus™ platform, we are uniquely positioned to interpret and analyze this data for actionable healthcare decisions across clinical decisions, diagnostics, therapeutics discovery and development.”
Mr. Voelker continued, “In order to achieve this level of interpretation, our decision engine leverages the full spectrum of available data – including molecular and end-to-end NGS testing, chemical, lab diagnostics and electronic medical records data. This enables Engineus™ to improve therapeutic efficacy, deepen safety research, optimize clinical trials, and enable new biomarker discoveries.”
To meet the growing needs of the global healthcare industry for evidence-based treatment decisions, Molecular Health plans to further expand the breadth of its platform beyond cancer, continuously adding new data types, diagnostic technologies and other disease entities and therapies, for example: metabolic diseases, cardiovascular diseases and immunotherapy.
About Molecular Health
Molecular Health GmbH is headquartered in Heidelberg, Germany and has the first registered medical device of its kind for personalized cancer medicine in Europe. In the United States, Molecular Health Inc., headquartered in Boston, Massachusetts, with a laboratory and support center in Greater Houston, Texas, is a wholly owned subsidiary of Molecular Health GmbH. To learn more, please visit: www.molecularhealth.com.
Media Contacts U.S.: Mark Rodgers +1 832-247-3068 [email protected] EMEA: Carla Mertens +49 6221 43851-2275 [email protected]
